Piramal Pharma discloses US FDA inspection observations at Turbhe facility

Piramal Pharma (BSE: 543635) has announced the conclusion of a US FDA General GMP inspection at its Turbhe facility, which ran from February 11th to February 17th, 2025. The inspection resulted in a Form-483 issuance, detailing six observations focused largely on improvements to procedures and practices and not related to data integrity. Piramal Pharma indicated that it is preparing a detailed response to these observations, which will be submitted to the agency within stipulated timelines. The company affirmed its commitment to maintaining the highest standards of compliance and expressed confidence in the effective resolution of the observations.